SUNPHARMA
Sun Pharmaceutical Industries Limited (SUNPHARMA) Stock Analysis
Sun Pharmaceutical Industries Limited is India's largest pharmaceutical company and a major global generics manufacturer. It develops and markets branded generics, complex injectables, and specialty therapies worldwide with strong US and India presence. The company has grown through acquisitions and R&D investments. It is listed on Indian stock exchanges.
Healthcare › Drug Manufacturers - Specialty & Generic
₹1,758.80
-0.07% 1W | +5.10% 52W
Market Cap
422.0k CR
P/E Ratio
34.9
52W High
₹2046.9
52W Low
₹1583.7
Div. Yield
0.91%
Beta
0.1
50 DMA
₹1864.7
200 DMA
₹1809
Profit Margin
20.2%
Inst. Own.
29.2%
✅ BOUNCE FROM SUPPORT
✅ BOUNCE FROM SUPPORT
Fundamentals
Profit & Loss
| Metric | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 11,941 | 12,192 | 12,381 | 11,983 | 12,653 | 13,291 | 13,675 | 12,959 | 13,851 | 14,478 | 15,521 | 14,612 | 15,300 |
| Expenses | 8,609 | 9,013 | 8,904 | 8,948 | 9,045 | 9,352 | 9,666 | 9,243 | 9,550 | 9,951 | 10,572 | 10,658 | 10,882 |
| Operating Profit | 3,332 | 3,179 | 3,477 | 3,035 | 3,608 | 3,939 | 4,009 | 3,716 | 4,302 | 4,527 | 4,948 | 3,954 | 4,418 |
| OPM % | 28% | 26% | 28% | 25% | 29% | 30% | 29% | 29% | 31% | 31% | 32% | 27% | 29% |
| Other Income | -118 | 294 | 180 | 504 | 533 | 354 | 149 | 251 | -354 | 470 | 89 | 458 | 520 |
| Interest | 81 | 49 | 35 | 74 | 62 | 69 | 52 | 49 | 75 | 100 | 78 | 86 | 100 |
| Depreciation | 651 | 633 | 622 | 650 | 655 | 626 | 631 | 664 | 701 | 730 | 732 | 775 | 739 |
| Profit before tax | 2,481 | 2,791 | 3,000 | 2,816 | 3,424 | 3,598 | 3,476 | 3,254 | 3,173 | 4,168 | 4,227 | 3,551 | 4,099 |
| Tax % | 19% | 14% | 14% | 5% | 16% | 16% | 16% | 34% | 27% | 25% | 20% | 23% | 29% |
| Net Profit | 2,006 | 2,385 | 2,561 | 2,659 | 2,861 | 3,037 | 2,913 | 2,154 | 2,293 | 3,125 | 3,381 | 2,710 | 2,901 |
| EPS in Rs | 8.43 | 9.90 | 10.52 | 11.06 | 11.82 | 12.67 | 12.10 | 8.96 | 9.50 | 13.00 | 14.04 | 11.31 | 12.06 |
| Metric | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 27,392 | 28,487 | 31,578 | 26,489 | 29,066 | 32,838 | 33,498 | 38,654 | 43,886 | 48,497 | 52,578 | 58,462 | 59,911 |
| Expenses | 19,498 | 20,313 | 21,476 | 20,858 | 22,689 | 25,855 | 25,028 | 28,397 | 32,235 | 35,479 | 37,464 | 41,961 | 42,063 |
| Operating Profit | 7,894 | 8,174 | 10,102 | 5,631 | 6,377 | 6,983 | 8,470 | 10,258 | 11,650 | 13,018 | 15,114 | 16,501 | 17,847 |
| OPM % | 29% | 29% | 32% | 21% | 22% | 21% | 25% | 27% | 27% | 27% | 29% | 28% | 30% |
| Other Income | 283 | -42 | 610 | -135 | -258 | 382 | -3,449 | -3,505 | 459 | 865 | 1,444 | 1,895 | 1,537 |
| Interest | 579 | 523 | 400 | 518 | 555 | 303 | 141 | 127 | 172 | 238 | 231 | 339 | 364 |
| Depreciation | 1,195 | 1,038 | 1,265 | 1,500 | 1,753 | 2,053 | 2,080 | 2,144 | 2,529 | 2,557 | 2,575 | 2,938 | 2,976 |
| Profit before tax | 6,403 | 6,571 | 9,048 | 3,479 | 3,810 | 5,010 | 2,799 | 4,481 | 9,408 | 11,088 | 13,752 | 15,119 | 16,045 |
| Tax % | 14% | 14% | 13% | 26% | 16% | 16% | 18% | 24% | 9% | 13% | 20% | 24% | |
| Net Profit | 5,476 | 5,658 | 7,846 | 2,542 | 3,208 | 4,172 | 2,272 | 3,389 | 8,513 | 9,610 | 10,965 | 11,509 | 12,117 |
| EPS in Rs | 21.92 | 18.89 | 29.03 | 8.73 | 11.11 | 15.69 | 12.10 | 13.64 | 35.32 | 39.91 | 45.55 | 47.84 | 50.41 |
| Dividend Payout % | 14% | 5% | 12% | 23% | 25% | 25% | 62% | 73% | 33% | 34% | 35% | 33% |
Growth — CAGR
| Metric | 3Y | 5Y | 10Y |
|---|---|---|---|
| Revenue CAGR | 10.0% | 12.0% | 7.0% |
| Profit CAGR | 13.0% | 17.0% | 10.0% |
Shareholding Pattern
Promoters54.48%
FIIs16.55%
DIIs20.12%
Public8.72%
Promoters54.48%
FIIs16.12%
DIIs20.72%
Public8.57%
Promoters54.48%
FIIs15.94%
DIIs21.00%
Public8.48%
Promoters54.48%
FIIs14.54%
DIIs22.06%
Public8.81%
Promoters52.68%
FIIs14.36%
DIIs22.27%
Public10.70%
Promoters54.48%
FIIs16.88%
DIIs19.18%
Public9.38%
Promoters54.48%
FIIs17.72%
DIIs18.71%
Public8.97%
Promoters54.48%
FIIs17.96%
DIIs18.58%
Public8.86%
Promoters54.48%
FIIs15.94%
DIIs21.00%
Public8.48%
Promoters52.68%
FIIs14.36%
DIIs22.27%
Public10.70%
SUNPHARMA
Holdings Analysis
Key strengths & risk signals
67
Overall
76
Fundamental
59
Technical
Risks (4)
OVERVALUED! PEG of 3.29 means expensive relative to growth rate.
WEAK POSITION! Current price (1758.8) is below both moving averages.
NEGATIVE MOMENTUM! Price declined across timeframes - down 0.1% (1 week), 5.1% (1 month), 9.0% (3 months).
POSITIVE YEAR! Stock gained 5.1% in the last year.
Strengths (4)
PERFECT RECORD! Revenue has grown consistently every year. Exceptional business stability.
BULLISH TREND! 50-day average (1864.7) is above 200-day average (1809.0) - positive signal.
LOW VOLATILITY! Beta of 0.10 - stable stock, less market risk.
TESTING SUPPORT! Stock is at key support level.
Fundamental & Technical Analysis
67Overall
76Fundamental
59Technical
Fundamental Breakdown
Growth Quality
22/30
Revenue CAGR: 10.4% (GOOD, 11/15). Profit CAGR: 10.6% (GOOD, 11/15).
Profit Margin
8/10
EXCELLENT EFFICIENCY! 20.2% profit margin - company keeps strong profits.
PEG Valuation
3/10
OVERVALUED! PEG of 3.29 means expensive relative to growth rate.
Dividend Yield
3/10
NEGLIGIBLE DIVIDEND! 0.91% yield - little to no income.
Debt to Equity
10/10
VERY LOW DEBT! D/E of 0.03 - excellent financial health.
Public Holding
20/20
VERY LESS PUBLIC HOLDING! 9.28% public ownership - strong promoter/institutional control.
Stability Index
10/10
PERFECT RECORD! Revenue has grown consistently every year. Exceptional business stability.
Technical Breakdown
Moving Averages
10/10
BULLISH TREND! 50-day average (1864.7) is above 200-day average (1809.0) - positive signal.
Price Position
2/10
WEAK POSITION! Current price (1758.8) is below both moving averages.
Trend Pattern
16/20
TESTING SUPPORT! Stock is at key support level.
52W Performance
4/10
POSITIVE YEAR! Stock gained 5.1% in the last year.
Volume Sentiment
15/30
BEARISH SENTIMENT! In last 30 days: 10 up days, 19 down days. Avg volume on up days: 1,534,317 vs down days: 1,535,270. Ratio: 1.0x
RSI
4/5
APPROACHING OVERSOLD! RSI at 37.0 - watch for reversal.
52W Range
2/5
LOWER HALF! Trading at 37.8% of 52W range - weakness visible.
Momentum
1/5
NEGATIVE MOMENTUM! Price declined across timeframes - down 0.1% (1 week), 5.1% (1 month), 9.0% (3 months).
Beta
5/5
LOW VOLATILITY! Beta of 0.10 - stable stock, less market risk.
SUNPHARMA
Concall / Investor Presentation
Earnings call transcripts & AI summaries
| Quarter | Concall | Summary |
|---|---|---|
| Q1FY272026-08-06 | Concall PDF | |
| Q4FY262026-05-29 | Concall PDF | |
| Q3FY262026-02-04 | Concall PDF | |
| Q2FY262025-11-11 | Concall PDF |
Peer Comparison
Healthcare · Drug Manufacturers - Specialty & Generic · 8 stocks
| Stock | Price | P/E | Profit Margin | Revenue CAGR 5Y | Profit CAGR 5Y | 52W Change | Stock Strength | Trendline | YoY Profit | QoQ Profit | YoY Revenue | QoQ Revenue |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SUNPHARMA | ₹1,758.80 | 34.9 | 20.2% | 10.4% | 10.6% | +5.1% | 67 | BOUNCE FROM SUPPORT | +27.0% | +6.7% | +10.1% | +4.3% |
| DIVISLAB | ₹9,144.50 | 83 | 26.0% | 11.0% | 12.1% | +36.4% | 74 | BREAKDOWN | +65.5% | +20.1% | +27.8% | +8.8% |
| TORNTPHARM | ₹4,558.90 | 72.8 | 13.9% | 13.3% | 20.2% | +27.9% | 71 | BREAKDOWN | +3.3% | +45.5% | +54.6% | +17.1% |
| ZYDUSLIFE | ₹1,123.00 | 25 | 15.8% | 16.5% | 37.0% | +14.2% | 76 | BREAKDOWN | -35.9% | -26.1% | +20.6% | +4.9% |
| LAURUSLABS | ₹2,060.10 | 101.8 | 15.0% | 3.8% | 4.0% | +124.3% | 62 | CONSOLIDATING UP | +125.5% | +31.7% | +29.1% | +11.9% |
| CIPLA | ₹1,325.10 | 31.8 | 12.0% | 7.2% | 11.5% | -16.2% | 59 | APPROACHING SUPPORT | -39.2% | +42.3% | +3.5% | +9.5% |
| DRREDDY | ₹1,233.00 | 31 | 10.0% | 11.0% | -1.7% | -2.0% | 59 | HIT RESISTANCE | -68.7% | +100.8% | -5.6% | +7.4% |
| AUROPHARMA | ₹1,666.90 | 26 | 10.6% | 10.7% | 22.1% | +52.4% | 75 | BREAKDOWN | +25.2% | +12.1% | +16.9% | +4.0% |
Data from TradeAlone · Updated daily
SUNPHARMA News
Sun Pharmaceutical Industries Limited (sunpharma) Gets FDA Approval for Ilumya® for Psoriatic Arthritis2026-10-30Sun Pharmaceutical Industries Limited Presents Long-term Data on Unloxcyt® at ESMO 20262026-10-23Sun Pharmaceutical Industries Limited Receives NCCN Category 2A Designation for Unloxcyt2026-10-20Sun Pharmaceutical Industries Limited Establishes Endowed Professorship at Mount Sinai2026-10-06Sun Pharmaceutical Industries Limited Announces Two-year Data for Leqselvi® in Severe Alopecia Areata2026-10-01Sun Pharmaceutical Industries Limited (sunpharma) Secures Global Licensing for Lerodalcibep, a PCSK9 Inhibitor2026-09-28Sun Pharmaceutical Industries Limited Joins U.S. Medicines Pricing and Access Commitments2026-09-01Sun Pharmaceutical Industries Limited Announces Organon Shareholder Approval for Acquisition2026-07-24Sun Pharmaceutical Industries Limited (sunpharma) Gains Approval to Market Generic Semaglutide in South Africa2026-07-15Sun Pharmaceutical Industries Limited to Present Pivotal Data on Unloxcyt™ at ASCO 20262026-05-26
